Cancer Genetics, Inc. Merger (Tables)
|3 Months Ended|
Mar. 31, 2021
|Business Combination and Asset Acquisition [Abstract]|
|Schedule of Preliminary Allocation of the Purchase Price Consideration||
The following details the preliminary allocation of the purchase price consideration:
Schedule of Preliminary Allocation of the Purchase Price Consideration
|Schedule of Unaudited Pro Forma Combined Financial Information||
The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2020:
Schedule of Unaudited Pro Forma Combined Financial Information
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef